Cargando…

The Cannabigerol Derivative VCE-003.2 Exerts Therapeutic Effects in 6-Hydroxydopamine-Lesioned Mice: Comparison with The Classic Dopaminergic Replacement Therapy

(1) Background: A cannabigerol aminoquinone derivative, so-called VCE-003.2, has been found to behave as a neuroprotective agent (administered both i.p. and orally) in different experimental models of Parkinson’s disease (PD) in mice. These effects were exerted through mechanisms that involved the a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rodríguez-Carreiro, Santiago, Navarro, Elisa, Muñoz, Eduardo, Fernández-Ruiz, Javier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527302/ https://www.ncbi.nlm.nih.gov/pubmed/37759872 http://dx.doi.org/10.3390/brainsci13091272

Ejemplares similares

Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration
por: Aguareles, José, et al.
Publicado: (2019)

VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington’s disease
por: Díaz-Alonso, Javier, et al.
Publicado: (2016)

Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor
por: García, Concepción, et al.
Publicado: (2018)

Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson’s Disease
por: Burgaz, Sonia, et al.
Publicado: (2019)

Neuroprotection with the Cannabidiol Quinone Derivative VCE-004.8 (EHP-101) against 6-Hydroxydopamine in Cell and Murine Models of Parkinson’s Disease
por: Burgaz, Sonia, et al.
Publicado: (2021)

Cannabidiol and Cannabigerol Exert Antimicrobial Activity without Compromising Skin Microbiota
por: Luz-Veiga, Mariana, et al.
Publicado: (2023)

Alleviation of Methamphetamine Sensitization by Partially Lesioning Dopaminergic Terminals with 6-Hydroxydopamine in Nucleus Accumbens
por: Chen, Shu-Chun, et al.
Publicado: (2021)

Biosynthesis of cannabigerol and cannabigerolic acid: the gateways to further cannabinoid production
por: Kearsey, Lewis J, et al.
Publicado: (2023)

Neurturin overexpression in dopaminergic neurons induces presynaptic and postsynaptic structural changes in rats with chronic 6-hydroxydopamine lesion
por: Reyes-Corona, David, et al.
Publicado: (2017)

The Origin and Biomedical Relevance of Cannabigerol
por: Jastrząb, Anna, et al.
Publicado: (2022)

Epothilone B Benefits Nigral Dopaminergic Neurons by Attenuating Microglia Activation in the 6-Hydroxydopamine Lesion Mouse Model of Parkinson’s Disease
por: Yu, Zhongyuan, et al.
Publicado: (2018)

VCE-004.8, A Multitarget Cannabinoquinone, Attenuates Adipogenesis and Prevents Diet-Induced Obesity
por: Palomares, Belen, et al.
Publicado: (2018)

Application of the Physical Disector Principle for Quantification of Dopaminergic Neuronal Loss in a Rat 6-Hydroxydopamine Nigral Lesion Model of Parkinson's Disease
por: Fabricius, Katrine, et al.
Publicado: (2017)

The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways
por: del Río, Carmen, et al.
Publicado: (2016)

Achyranthes bidentata polypeptide protects dopaminergic neurons from apoptosis induced by rotenone and 6-hydroxydopamine
por: Peng, Su, et al.
Publicado: (2018)

Protective Effect of Amber Extract on Human Dopaminergic Cells against 6-Hydroxydopamine-Induced Neurotoxicity
por: Luo, Yuening, et al.
Publicado: (2022)

Stochastic Modeling of Smartphones GNSS Observations Using LS-VCE and Application to Samsung S20
por: Zangenehnejad, Farzaneh, et al.
Publicado: (2023)

0032. Relationship between microcirculatory alterations and venous-to-arterial carbon dioxide differences in patients with septic shock
por: Ospina-Tascón, GA, et al.
Publicado: (2014)

Anti-Biofilm Activity of Cannabigerol against Streptococcus mutans
por: Aqawi, Muna, et al.
Publicado: (2021)

Anti-Bacterial Properties of Cannabigerol Toward Streptococcus mutans
por: Aqawi, Muna, et al.
Publicado: (2021)

Acute Cannabigerol Administration Lowers Blood Pressure in Mice
por: Vernail, Victoria L., et al.
Publicado: (2022)

Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy
por: Navarrete, Carmen, et al.
Publicado: (2018)

Destruction of Dopaminergic Neurons in the Midbrain by 6-Hydroxydopamine Decreases Hippocampal Cell Proliferation in Rats: Reversal by Fluoxetine
por: Suzuki, Katsuaki, et al.
Publicado: (2010)

Erythropoietin improves neurobehavior by reducing dopaminergic neuron loss in a 6-hydroxydopamine-induced rat model
por: QI, CHEN, et al.
Publicado: (2014)

Abrogation of the Circadian Nuclear Receptor REV-ERBα Exacerbates 6-Hydroxydopamine-Induced Dopaminergic Neurodegeneration
por: Kim, Jeongah, et al.
Publicado: (2018)

Prosaposin PS18 reduces dopaminergic neurodegeneration in a 6-hydroxydopamine rat model of Parkinson’s disease
por: Wu, Kuo-Jen, et al.
Publicado: (2023)

Chondroitinase ABC reduces dopaminergic nigral cell death and striatal terminal loss in a 6-hydroxydopamine partial lesion mouse model of Parkinson’s disease
por: Fletcher, Edward J. R., et al.
Publicado: (2019)

Subtle Cardiovascular Dysfunction in the Unilateral 6-Hydroxydopamine-Lesioned Rat
por: Slack, K., et al.
Publicado: (2010)

EHMTI-0032. Persistence and switching characteristics among chronic migraine patient population: a retrospective claims analysis
por: Hepp, Z, et al.
Publicado: (2014)

Cannabigerol Prevents Quorum Sensing and Biofilm Formation of Vibrio harveyi
por: Aqawi, Muna, et al.
Publicado: (2020)

Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives
por: Calapai, Fabrizio, et al.
Publicado: (2022)

Chronic Cannabigerol as an Effective Therapeutic for Cisplatin-Induced Neuropathic Pain
por: Nachnani, Rahul, et al.
Publicado: (2023)

Modafinil Improves Catalepsy in a Rat 6-Hydroxydopamine Model of Parkinson’s Disease; Possible Involvement of Dopaminergic Neurotransmission
por: Vajdi-Hokmabad, Reza, et al.
Publicado: (2017)

NOD2 promotes dopaminergic degeneration regulated by NADPH oxidase 2 in 6-hydroxydopamine model of Parkinson’s disease
por: Cheng, Li, et al.
Publicado: (2018)

Both Intracranial and Intravenous Administration of Functionalized Carbon Nanotubes Protect Dopaminergic Neuronal Death from 6-Hydroxydopamine
por: Kim, Ok-Hyeon, et al.
Publicado: (2020)

Anaplasma phagocytophilum APH0032 Is Exposed on the Cytosolic Face of the Pathogen-Occupied Vacuole and Co-opts Host Cell SUMOylation
por: Oki, Aminat T., et al.
Publicado: (2016)

Electroacupuncture Produces the Sustained Motor Improvement in 6-Hydroxydopamine-Lesioned Mice
por: Yu, Yan, et al.
Publicado: (2016)

Chlorogenic Acid Exerts Beneficial Effects in 6-Hydroxydopamine-Induced Neurotoxicity by Inhibition of Endoplasmic Reticulum Stress
por: Shan, Shihai, et al.
Publicado: (2019)

Effects of Subthalamic Nucleus Lesions and Stimulation upon Corticostriatal Afferents in the 6-Hydroxydopamine-Lesioned Rat
por: Walker, Ruth H., et al.
Publicado: (2012)

Neuroprotective Effects of Erucin against 6-Hydroxydopamine-Induced Oxidative Damage in a Dopaminergic-like Neuroblastoma Cell Line
por: Tarozzi, Andrea, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_o8u4po1hk6fdcep3ueidn9ud8o